New Data for florbetaben F18 from Piramal Imaging

 

October 2013 — Results from five studies evaluating Piramal Imaging’s PET amyloid imaging agent, florbetaben F18, were presented at Alzheimer’s Association International Conference (AAIC). “The studies presented at this year’s conference continue to reinforce the strength of the florbetaben F18 development program. We are hopeful CMS will consider the increasing evidence why beta-amyloid imaging is a medically necessary diagnostic tool for appropriate Medicare populations,” said Dr. Ludger Dinkelborg, Director of the Board, Piramal Imaging SA. Florbetaben is under review by the FDA and European Medicines Agency for use in the visual detection of beta-amyloid in the brains of adults with cognitive impairment who are being evaluated for Alzheimer’s disease and other causes of cognitive decline. Look for more coverage in next month’s edition of Practical Neurology.

 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.

 
  • BRYN MAWR COMMUNICATIONS III, LLC